| scholarly article | Q13442814 |
| P50 | author | Ronald Swanstrom | Q62641484 |
| P2093 | author name string | Celia A Schiffer | |
| Sook-Kyung Lee | |||
| Nancy Cheng | |||
| William Janzen | |||
| Marc Potempa | |||
| Emily Hull-Ryde | |||
| P2860 | cites work | The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles | Q21245046 |
| Polarization of the fluorescence of macromolecules. I. Theory and experimental method | Q24531310 | ||
| Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men | Q24612082 | ||
| Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system | Q24628961 | ||
| Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 | Q25938983 | ||
| Statistical methods for assessing agreement between two methods of clinical measurement | Q26778461 | ||
| Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease | Q27637329 | ||
| Structure of the N-terminal 283-residue fragment of the immature HIV-1 Gag polyprotein | Q27639039 | ||
| X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease | Q27639157 | ||
| Structure of the Antiviral Assembly Inhibitor CAP-1 Complex with the HIV-1 CA Protein | Q27647971 | ||
| Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere | Q27656274 | ||
| HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention | Q27666355 | ||
| Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA Protein | Q27678471 | ||
| Structure of the immature retroviral capsid at 8 Å resolution by cryo-electron microscopy | Q27681296 | ||
| The Mechanism of HIV-1 Core Assembly: Insights from Three-Dimensional Reconstructions of Authentic Virions | Q27702100 | ||
| ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans | Q27729982 | ||
| Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases | Q27730719 | ||
| Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease | Q27748305 | ||
| Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes | Q27860623 | ||
| Specific covalent labeling of recombinant protein molecules inside live cells | Q28276029 | ||
| Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives | Q28323202 | ||
| Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease | Q28330893 | ||
| Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection | Q28369033 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. | Q29619254 | ||
| A peptide inhibitor of HIV-1 assembly in vitro | Q33220259 | ||
| Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor | Q33669002 | ||
| HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice | Q34529834 | ||
| Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease | Q35921690 | ||
| Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis | Q36266587 | ||
| Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha | Q36446606 | ||
| Mutations in multiple domains of Gag drive the emergence of in vitro resistance to the phosphonate-containing HIV-1 protease inhibitor GS-8374. | Q36506829 | ||
| Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation | Q36944553 | ||
| PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing | Q37089562 | ||
| Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. | Q37235740 | ||
| Structure and assembly of immature HIV | Q37237053 | ||
| HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. | Q37447762 | ||
| Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor | Q37583444 | ||
| HIV-1 assembly, budding, and maturation | Q38023864 | ||
| High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates | Q38550993 | ||
| High-resolution structure of a retroviral capsid hexameric amino-terminal domain | Q39272732 | ||
| Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity | Q39621109 | ||
| Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization | Q39641782 | ||
| Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population | Q39642550 | ||
| The prevalence of antiretroviral drug resistance in the United States | Q39687529 | ||
| Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein | Q39748566 | ||
| The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. | Q40042979 | ||
| Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag. | Q40326740 | ||
| Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles | Q40357793 | ||
| A novel assay for the DNA strand-transfer reaction of HIV-1 integrase | Q40399098 | ||
| Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat | Q40750425 | ||
| Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly | Q41047831 | ||
| Assay of proteolytic enzymes by the fluorescence polarization technique | Q41476686 | ||
| Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids | Q42285617 | ||
| 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro | Q42424208 | ||
| A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle | Q42546287 | ||
| Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents | Q42555749 | ||
| A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion | Q42560226 | ||
| A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease | Q42872702 | ||
| High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor | Q43227082 | ||
| In vitro analysis of an RNA binding site within the N-terminal 30 amino acids of the southern cowpea mosaic virus coat protein | Q43695698 | ||
| Antiviral inhibition of the HIV-1 capsid protein | Q44380725 | ||
| The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor | Q45432280 | ||
| Fluorescence anisotropy assay for proteolysis of specifically labeled fusion proteins. | Q54494902 | ||
| Measurement of specific protease activity utilizing fluorescence polarization | Q73286573 | ||
| Implications for viral capsid assembly from crystal structures of HIV-1 Gag(1-278) and CA(N)(133-278) | Q80280623 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 29 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 4929-4940 | |
| P577 | publication date | 2013-07-11 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid | |
| P478 | volume | 52 |
| Q34435796 | Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs |
| Q41467248 | Fluorescence polarization assays in high-throughput screening and drug discovery: a review |
| Q58597952 | HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites |
| Q92233282 | Methods to analyze STUbL activity |
| Q39294730 | Recent developments in protease activity assays and sensors. |
| Q38818907 | Stapled peptides: providing the best of both worlds in drug development |
Search more.